Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2025-12-15 @ 10:04 PM
Study NCT ID:
NCT05721300
Status:
None
Last Update Posted:
2023-02-10 00:00:00
First Post:
2022-12-22 00:00:00
Brief Title:
Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer
Sponsor:
Zhongshan Hospital Xiamen Fudan University
Organization:
Zhongshan Hospital (Xiamen), Fudan University
Study Overview
Official Title:
Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer
Status:
None
Status Verified Date:
2022-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to test the outcomes of HBsAg(+) patients in the treatments of NAs vs NAs plus IFN . The main questions it aims to answer are:
1. Clinical effect analysis of nucleoside analogs (NAs) group a group and NAs plus interferon group after 48 weeks of treatment;
2. Repetitive effect and time effect of different drug treatment at different follow-up time points;
3. To evaluate the difference of therapeutic effect of NAs or NAs combined with interferon;
4. Follow up and compare the incidence of early liver cancer in each group. Participants will be asked to receive NAs or NAs combined with interferon treatments, and Regular blood sampling and color ultrasound examination.
Researchers will compare control group to see if occurrence of liver cancer.
1. Clinical effect analysis of nucleoside analogs (NAs) group a group and NAs plus interferon group after 48 weeks of treatment;
2. Repetitive effect and time effect of different drug treatment at different follow-up time points;
3. To evaluate the difference of therapeutic effect of NAs or NAs combined with interferon;
4. Follow up and compare the incidence of early liver cancer in each group. Participants will be asked to receive NAs or NAs combined with interferon treatments, and Regular blood sampling and color ultrasound examination.
Researchers will compare control group to see if occurrence of liver cancer.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None